Many people experience withdrawal-like symptoms that are common across the GLP-1 class, and the timeline of symptom emergence follows the pharmacokinetic clearance curve
The Results: Tirzepatide Wins By a Significant Margin At 72 weeks, the results were unambiguous: Tirzepatide: average body weight loss of 20.2% Semaglutide: average body weight loss of 13.7% That gap 6.5 percentage points is not a small difference
But the weight itself tends to return
GIP-1s and GIPs are not appropriate for pregnant women and individuals with severe gastrointestinal conditions such as gastroparesis and inflammatory bowel disease
Always ensure responsible supplementation and seek medical advice when necessary
Infused with a powerful blend of Glutathione, Hyaluronic, Aloe, Acai, Blueberry, Vitamin C and E